肌萎縮側索硬化症治療市場規模、佔有率和成長分析（按治療方法、類型、分銷管道和地區）- 產業預測 2025-2032

2023 年肌萎縮側索硬化症治療市場規模價值 7.1145 億美元，預計將從 2024 年的 7.52 億美元擴大到 2032 年的 11.7171 億美元，預測期內（2025-2032 年）的複合年成長率為 5.7%。

肌萎縮側索硬化症 (ALS)，也稱為盧格里格氏症，是一種進行性神經退化性疾病，由於中樞神經系統神經細胞受損而影響隨意肌控制。症狀包括肌肉痙攣、僵硬和無力，導致吞嚥、說話和運動等基本功能喪失。大約 90-95% 的 ALS 病例是散發性的，其餘的是遺傳性ALS (FALS)，具有很大的遺傳成分，主要是由於 C9ORF72 基因突變造成的。目前，尚無可以治癒 ALS的治療方法，但是，透過藥物治療和幹細胞治療等先進治療方法進行症狀管理非常重要，並有望推動全球 ALS 治療市場的成長。持續的研究和創新對於應對這項挑戰至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 技術進步
• 監管格局
• 專利分析

肌萎縮側索硬化症治療市場規模（依治療方法）

• 市場概況
• 藥品
• 幹細胞治療
• 物理治療
• 語言治療

肌萎縮側索硬化症治療市場規模（按類型）

• 市場概況
• 散發性 ALS
• 遺傳性ALS

肌萎縮側索硬化症治療市場規模（依分銷管道分類）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

肌萎縮側索硬化症治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Mitsubishi Tanabe Pharma Corporation（Japan）
• Biogen Inc.（USA）
• BrainStorm Cell Therapeutics Inc.（USA）
• Amylyx Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Sanofi（France）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• F. Hoffmann-La Roche Ltd（Switzerland）
• AB Science（France）
• Sun Pharmaceutical Industries Ltd.（India）
• Orion Corporation（Finland）
• CORESTEMCHEMON Inc.（South Korea）
• Cytokinetics, Inc.（USA）
• MediciNova, Inc.（USA）
• Mitsubishi Chemical Group Corporation（Japan）
• Apellis Pharmaceuticals, Inc.（USA）
• Denali Therapeutics Inc.（USA）
• Genentech, Inc.（USA）
• Treeway BV（Netherlands）

結論和建議

Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 711.45 million in 2023 and is poised to grow from USD 752.0 million in 2024 to USD 1171.71 million by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder affecting voluntary muscle control due to nerve cell damage in the central nervous system. Symptoms include muscle twitching, stiffness, and weakness, leading to the loss of essential functions like swallowing, speaking, and mobility. Approximately 90-95% of ALS cases are sporadic, while familial ALS (FALS) accounts for the remainder, with significant genetic components, primarily the C9ORF72 gene mutation. While there is currently no cure for ALS, symptom management through medications and advanced therapies like stem cell treatments is critical and expected to fuel the growth of the global ALS treatment market. Continued research and innovation are essential in addressing this challenging condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyotrophic Lateral Sclerosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyotrophic Lateral Sclerosis Treatment Market Segments Analysis

Global Amyotrophic Lateral Sclerosis Treatment Market is segmented by Treatment, Type, Distribution Channel and region. Based on Treatment, the market is segmented into Medication, Stem Cell Therapy, Physical Therapy and Speech Therapy. Based on Type, the market is segmented into Sporadic ALS and Familial ALS. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyotrophic Lateral Sclerosis Treatment Market

The growth of the Amyotrophic Lateral Sclerosis (ALS) treatment market is anticipated to be significantly influenced by the increasing prevalence of the disease. Data from the Centers for Disease Control and Prevention (CDC) indicated that in 2016, approximately 14,500 to 15,000 individuals in the United States were living with ALS, with around 5,000 new diagnoses occurring each year. Furthermore, globally, ALS affects about 2 to 5 individuals per 100,000. The rise in sedentary lifestyles and a growing elderly population also contribute to the heightened demand for both targeted and symptomatic treatments, which will likely stimulate the ALS treatment market in the coming years.

Restraints in the Amyotrophic Lateral Sclerosis Treatment Market

The amyotrophic lateral sclerosis (ALS) treatment market faces several significant restraints that are likely to hinder its growth during the forecast period. The high cost of treatment is a primary concern, as ALS is a rare condition, leading to exorbitant expenses that can reach approximately $200,000 annually, including medication like Edaravone, which alone costs around $145,000. Additionally, there is a general lack of awareness regarding ALS, which further limits patient access to treatment options. Moreover, the uncertainty surrounding the effectiveness of these costly treatments, associated with low survival rates, presents a substantial challenge for market expansion and patient confidence.

Market Trends of the Amyotrophic Lateral Sclerosis Treatment Market

The amyotrophic lateral sclerosis (ALS) treatment market is witnessing significant growth driven by the increasing prevalence of neurodegenerative disorders amidst busy lifestyles and rising incidences of ALS. The expanding geriatric population, particularly vulnerable to such conditions, is further propelling market expansion. Additionally, various NGOs and private organizations are actively promoting awareness campaigns focused on ALS diagnosis and treatment, fostering a more informed patient base and enhancing market outlook. The emergence of targeted symptomatic treatments aimed at alleviating ALS symptoms is also contributing to market growth, reflecting a robust trend towards more personalized and effective therapeutic solutions in the ALS landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Advancement
• Regulatory Landscape
• Patent Analysis

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Stem Cell Therapy
• Physical Therapy
• Speech Therapy

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Sporadic ALS
• Familial ALS

Global Amyotrophic Lateral Sclerosis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Amyotrophic Lateral Sclerosis Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BrainStorm Cell Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amylyx Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CORESTEMCHEMON Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytokinetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediciNova, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Chemical Group Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Denali Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treeway B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations